Hubei Biocause Heilen Pharmaceutical Third Quarter 2024 Earnings: EPS: CN¥0.021 (vs CN¥0.11 in 3Q 2023)

Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Third Quarter 2024 Results

Key Financial Results

• Revenue: CN¥92.1m (down 33% from 3Q 2023).
• Net income: CN¥6.17m (down 80% from 3Q 2023).
• Profit margin: 6.7% (down from 23% in 3Q 2023). The decrease in margin was driven by lower revenue.
• EPS: CN¥0.021 (down from CN¥0.11 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hubei Biocause Heilen Pharmaceutical shares are up 22% from a week ago.

Risk Analysis

Be aware that Hubei Biocause Heilen Pharmaceutical is showing 3 warning signs in our investment analysis and 2 of those can't be ignored...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.